Real evaluation and clinical data analysis of the therapeutic effect of Ixazomib (Enleri)

Ixazomib (Ixazomib) is an oral proteasome inhibitor mainly used to treat multiple myeloma (Multiple Myeloma, MM). Compared with injectable proteasome inhibitors (such as bortezomib), the oral administration of ixazomib significantly improves patients' medication convenience and quality of life. Its mechanism of action is by inhibiting the activity of the 26S proteasome, blocking the protein degradation pathway of tumor cells, causing myeloma cells to accumulate abnormal proteins and induce apoptosis, thereby achieving anti-tumor effects.

In thePhase III clinical trialTOURMALINE-MM1, ixazomib combined with lenalidomide (Lenalidomide) and dexamethasone (Dexamethasone) have shown significant efficacy in patients with multiple myeloma who have received one to three previous treatments. The study results showed that the median progression-free survival (PFS) of the combination treatment group was 20.6 months, which was significantly better than the 14.7 months of the control group. The overall response rate (ORR) reached 78%, while the complete response rate (CR) was approximately 15%. These data suggest that the ixazomib combination regimen has promising antitumor activity in patients with relapsed or refractory myeloma.

Real-world studies show that the efficacy of ixazomib in actual clinical applications is similar to clinical trial results. In a multicenter retrospective analysis, patients who received ixazomib combined with lenalidomide and dexamethasone had an overall response rate of 70%-75% and a median progression-free survival of approximately 18-22 months. Patients have high compliance with oral administration and the drug is well tolerated, which can significantly reduce the discomfort and hospitalization burden caused by injections. These real-world data further validate the clinical value of ixazomib, especially for long-term maintenance treatment.

Common side effects of ixazomib combination regimen include hematological toxicity (such as neutropenia, thrombocytopenia, anemia), gastrointestinal reactions (such as nausea, diarrhea, constipation), fatigue and peripheral neuropathy. Most adverse reactions are mild to moderate and can be alleviated by adjusting the dose or intermittent administration. The incidence of serious adverse reactions is relatively low, and kidney and liver damage are rare. Patients need to regularly monitor blood routine, liver and kidney function and nervous system indicators during medication, and adjust the dose according to tolerance to ensure efficacy while controlling side effects.

Overall, ixazomib showed significant efficacy and good tolerability in patients with relapsed or refractory multiple myeloma. The oral administration mode improves patients' quality of life and treatment compliance and is ideal for long-term maintenance treatment. In clinical application, an individualized plan should be formulated based on the patient's previous treatment history, renal and renal function, hematological status and side effect tolerance, and efficacy and safety indicators should be reviewed regularly. Based on the results of various studies, ixazomib has become an important anti-tumor drug in the treatment of multiple myeloma, providing patients with a new long-term management strategy.

Reference materials:https://www.drugs.com/